CUMBERLAND, R.I.--(BUSINESS WIRE)--Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced the presentation of a scientific poster summarizing the results of a pharmacokinetic study for its abuse-deterrent, sustained release oral oxycodone formulation (COL-003). The poster, entitled, “Abuse-Deterrent Properties and Pharmacokinetics of a Novel Sustained Release Formulation of Oxycodone for the Treatment of Moderate to Severe Pain”, will be presented at the 27th Annual Scientific Meeting of the American Pain Society (APS), May 8-10, in Tampa, Florida. The poster will be displayed and presented on May 8th.
